ArticleAdvances in radiation oncology2026
Commencement of Hypofractionated Adjuvant Radiation Therapy in Intermediate-Risk Oral Cavity Cancer: A Phase 1 Study Protocol (CHARIOT-1).
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Oral squamous cell carcinoma (OSCC) contributes substantially to the cancer burden in India. The standard treatment involves surgical excision followed by adjuvant radiation therapy (RT) or chemo-RT, based on histopathological risk factors. Although conventionally fractionated RT remains the current standard, limited data exist on the role of hypofractionated RT (HFRT) in adjuvant setting. This trial aims to establish maximum tolerated dose and fractionation (MTDF) of adjuvant HFRT in OSCC. Secondary objectives include analyzing acute, consequential, and late toxicities associated with HFRT. Methods and Materials: This paper describes an ongoing single-institute phase 1 trial conducted at a tertiary cancer center in India. Eligible patients with primary OSCC who have undergone radical surgery and require adjuvant RT alone will be enrolled. The study consists of 2 parts: part A (dose escalation) to determine the MTDF using a modified rolling 6 design at 3 escalating dose levels, followed by part B (dose expansion) to assess the additional toxicity profile by randomizing patients between the MTDF (n = 12) and the preceding dose level (MTDF-1) (n = 12). Randomization will be performed using a minimization technique, and stratification factors include age, primary tumor location, and nodal disease burden. The sample size for the trial is 42 (18 in part A and 24 in part B). Adjuvant HFRT doses will be optimized using a biologically effective dose model, and all treatments will be delivered with image guided RT. Predefined stopping rules will be applied for dose-limiting toxicities, which will be monitored by an independent adjunct committee.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.